Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-377.94M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 18.82 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -145.91% |
| Return on Assets (Trailing 12 Months) | -96.68% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.95 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.95 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.41 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.88 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.29 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.43 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 114.88M |
| Free Float | 99.60M |
| Market Capitalization | $5.20B |
| Average Volume (Last 20 Days) | 1.14M |
| Beta (Past 60 Months) | 0.70 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |